193357-76-5Relevant academic research and scientific papers
Method for treating diseased-related or drug-induced dyskinesias
-
, (2008/06/13)
Dyskinesias in humans are treated by administering a therapeutically effective dose of an NR1A/2B site-selective NMDA receptor antagonist compound to a human suffering therefrom.
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
-
, (2011/05/18)
PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.
4-HYDROXY-PIPERODINE DERIVATIVES
-
, (2008/06/13)
The present invention relates to compounds of the formula STR1 wherein x is--O--,--NH--,--CH 2--,--CH=,--CO 2--,--CONH--,--CON(lower alkyl)--,--S--and--SO 2--; R. sup.1-R. sup.4 are, independently from each other hydrogen, halogen, hydroxy, amino, nitro, lower-alkyl-sulfonylamido, 1-or 2-imidazolyl, 1-(1,2,4-triazolyl) or acetamido;R 5, R 6 are, independently from each other hydrogen, lower-alkyl, hydroxy, lower alkoxy or oxo;R. sup.7-R 10 are, independently from each other hydrogen, lower-alkyl, halogen, trifluoromethyl or lower-alkoxy;n is 0 or 1; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers.
